Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Farmers Insurance
Dow
Federal Trade Commission
Merck
Johnson and Johnson
Express Scripts
Healthtrust
Medtronic

Generated: May 27, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,750,237

« Back to Dashboard

Which drugs does patent 6,750,237 protect, and when does it expire?

Patent 6,750,237 protects ZOMIG and is included in one NDA.

Protection for ZOMIG has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-nine patent family members in twenty-eight countries.
Summary for Patent: 6,750,237
Title: Pharmaceutical formulations containing zolmitriptan
Abstract:A pharmaceutical formulation of the 5HT1-agonist, zolmitriptan, for use in intranasal administration. The formulation is useful in treating migraine and related disorders.
Inventor(s): Dearn; Alan Roy (Ware, GB), Williamson; Sarah Louise (Ware, GB), Summers; Simon John (Ware, GB), Coomber; Trevor John (Ware, GB)
Assignee: AstraZeneca AB (London, GB)
Application Number:10/129,773
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,750,237
Patent Claim Types:
see list of patent claims
Composition; Formulation; Device;

Drugs Protected by US Patent 6,750,237

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Astrazeneca ZOMIG zolmitriptan SPRAY;NASAL 021450-003 Sep 16, 2013 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Astrazeneca ZOMIG zolmitriptan SPRAY;NASAL 021450-004 Sep 30, 2003 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,750,237

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9928578Dec 03, 1999
PCT Information
PCT FiledNovember 28, 2000PCT Application Number:PCT/GB00/04528
PCT Publication Date:June 07, 2001PCT Publication Number: WO01/39772

Non-Orange Book US Patents Family Members for Patent 6,750,237

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,220,767 Pharmaceutical formulations containing zolmitriptan ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 6,750,237

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 291914 ➤ Try a Free Trial
Australia 1715701 ➤ Try a Free Trial
Australia 778092 ➤ Try a Free Trial
Brazil 0016138 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Deloitte
Cipla
Argus Health
Baxter
McKinsey
Daiichi Sankyo
Julphar
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.